FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W89888945> ?p ?o ?g. }

• W89888945 abstract "Protein aggregation is commonly encountered during the manufacture of protein-based bioproducts in processing such as protein expression, purification, refolding, shipping and storage (Volkin and Middaugh, 1992; Brange, 2000). Aggregation may shorten the shelf-life of pharmaceutical proteins (Frokjaer and Otzen, 2005) and induce severe hypersensitivity (Rosenberg, 2006). In addition, several diseases ranging from Alzheimer’s disease to cystic fibrosis are associated with protein aggregation in the form of amyloid fibrils and plaques (Dobson, 1999; Luheshi et al., 2008). Hence, studies on protein aggregation, especially those dealing with high concentrations of proteins, are highly demanded in both academic and industrial laboratories. To address the aforementioned issues, physicochemical factors affecting protein aggregation were investigated systematically in this project. Strategies were developed to inhibit protein aggregation during renaturation and to enhance protein stability against aggregation during and after production, especially when dealing with high protein concentrations. ∆5-3-Ketosteroid isomerase (KSI) was used as a model for aggregation studies during protein renaturation due to its intrinsic aggregation properties. KSI was overexpressed as inclusion bodies (IBs) in Escherichia coli (E. coli). Cost- and time-efficient combination of chemical extraction and one-step affinity purification ensured the production of denatured KSI with high purity at high yield. Several key factors, including protein concentration and ionic strength, were determined to greatly influence KSI aggregation during renaturation. Polymer addition (PEG 3000 and Eudragit S-100) was found to alter KSI aggregation behaviour in a polymer-specific manner, as quantified using reversed phase-high performance liquid chromatography (RP-HPLC) analysis. Light scattering for second virial coefficient (SVC) measurement, surface plasmon resonance (SPR), and microfluidics were applied to study the fundamental mechanism of protein aggregation. Lysozyme was further introduced as a control protein for comparison with KSI. A rapid lumped method was established to measure specific refractive index (∂n/∂c) and SVC values for KSI and lysozyme, which provided quantitative and qualitative information on thermodynamic interactions of molecules in solution. SPR and microfluidics were also used to explore protein aggregation properties. To our best knowledge, it is the first time SPR and microfluidics have been used to investigate protein aggregation behaviour. Both SPR and microfluidics present significant potential for assessing protein aggregation and diagnosis or drug screening of protein aggregation related diseases. The chemical and physical stability of proteins needs to be maintained after successful refolding to ensure an acceptably long shelf life, especially at high protein concentration (Chang and Hermsdorf, 2002). The pharmaceutical effects of lectins on cell growth provided incentive for studies to improve their stability. Human galectin-2 (hGal-2, a homodimeric lectin) was used as a study model in this project. Mutations were introduced at one of the two Cys residues (C57A, C57M, and C57S). Only the C57M variant was highly expressed in bacteria in soluble form. No aggregate of this mutant was detected during 3 weeks of storage. hGal-2 C57M also facilitated site-directed introduction of poly(ethylene glycol) (PEG) into the remaining sulfhydryl group (Cys75). Product analysis revealed rather complete conjugation with one PEG chain per protein subunit in homodimer. Neither secondary structure alteration nor the absence of binding ability to a glycoprotein (asialofetuin) was observed. The results document the feasibility of tailoring a human galectin for enhanced stability against aggregation as well as monoPEGylation, which enables further testing of biological properties including functionality as a growth regulator and the serum clearance rate of hGal-2." @default.
• W89888945 created "2016-06-24" @default.
• W89888945 creator A5090366405 @default.
• W89888945 date "2009-03-01" @default.
• W89888945 modified "2023-09-27" @default.
• W89888945 title "Physicochemical Factors Affecting Protein Aggregation: Biomolecular Engineering of Proteins for Enhanced Stability" @default.
• W89888945 hasPublicationYear "2009" @default.
• W89888945 type Work @default.
• W89888945 sameAs 89888945 @default.
• W89888945 citedByCount "0" @default.
• W89888945 crossrefType "journal-article" @default.
• W89888945 hasAuthorship W89888945A5090366405 @default.
• W89888945 hasConcept C104317684 @default.
• W89888945 hasConcept C12554922 @default.
• W89888945 hasConcept C136238340 @default.
• W89888945 hasConcept C14631669 @default.
• W89888945 hasConcept C155672457 @default.
• W89888945 hasConcept C171250308 @default.
• W89888945 hasConcept C178790620 @default.
• W89888945 hasConcept C179104552 @default.
• W89888945 hasConcept C184651966 @default.
• W89888945 hasConcept C185592680 @default.
• W89888945 hasConcept C187428577 @default.
• W89888945 hasConcept C192562407 @default.
• W89888945 hasConcept C203750385 @default.
• W89888945 hasConcept C2777633098 @default.
• W89888945 hasConcept C43617362 @default.
• W89888945 hasConcept C547475151 @default.
• W89888945 hasConcept C55493867 @default.
• W89888945 hasConcept C86803240 @default.
• W89888945 hasConcept C8985478 @default.
• W89888945 hasConceptScore W89888945C104317684 @default.
• W89888945 hasConceptScore W89888945C12554922 @default.
• W89888945 hasConceptScore W89888945C136238340 @default.
• W89888945 hasConceptScore W89888945C14631669 @default.
• W89888945 hasConceptScore W89888945C155672457 @default.
• W89888945 hasConceptScore W89888945C171250308 @default.
• W89888945 hasConceptScore W89888945C178790620 @default.
• W89888945 hasConceptScore W89888945C179104552 @default.
• W89888945 hasConceptScore W89888945C184651966 @default.
• W89888945 hasConceptScore W89888945C185592680 @default.
• W89888945 hasConceptScore W89888945C187428577 @default.
• W89888945 hasConceptScore W89888945C192562407 @default.
• W89888945 hasConceptScore W89888945C203750385 @default.
• W89888945 hasConceptScore W89888945C2777633098 @default.
• W89888945 hasConceptScore W89888945C43617362 @default.
• W89888945 hasConceptScore W89888945C547475151 @default.
• W89888945 hasConceptScore W89888945C55493867 @default.
• W89888945 hasConceptScore W89888945C86803240 @default.
• W89888945 hasConceptScore W89888945C8985478 @default.
• W89888945 hasLocation W898889451 @default.
• W89888945 hasOpenAccess W89888945 @default.
• W89888945 hasPrimaryLocation W898889451 @default.
• W89888945 hasRelatedWork W1964347315 @default.
• W89888945 hasRelatedWork W1965569919 @default.
• W89888945 hasRelatedWork W1973011252 @default.
• W89888945 hasRelatedWork W1977500946 @default.
• W89888945 hasRelatedWork W1995361735 @default.
• W89888945 hasRelatedWork W2006596346 @default.
• W89888945 hasRelatedWork W2007492537 @default.
• W89888945 hasRelatedWork W2018989948 @default.
• W89888945 hasRelatedWork W2019210215 @default.
• W89888945 hasRelatedWork W2033291213 @default.
• W89888945 hasRelatedWork W2048049130 @default.
• W89888945 hasRelatedWork W2061602810 @default.
• W89888945 hasRelatedWork W2290826925 @default.
• W89888945 hasRelatedWork W2331046839 @default.
• W89888945 hasRelatedWork W2400476916 @default.
• W89888945 hasRelatedWork W2896777916 @default.
• W89888945 hasRelatedWork W2918099823 @default.
• W89888945 hasRelatedWork W318457709 @default.
• W89888945 hasRelatedWork W3209113390 @default.
• W89888945 hasRelatedWork W75652269 @default.
• W89888945 isParatext "false" @default.
• W89888945 isRetracted "false" @default.
• W89888945 magId "89888945" @default.
• W89888945 workType "article" @default.